EP4379067A1 - Iridoid derivatives and their use in a tanning process - Google Patents

Iridoid derivatives and their use in a tanning process Download PDF

Info

Publication number
EP4379067A1
EP4379067A1 EP22306769.5A EP22306769A EP4379067A1 EP 4379067 A1 EP4379067 A1 EP 4379067A1 EP 22306769 A EP22306769 A EP 22306769A EP 4379067 A1 EP4379067 A1 EP 4379067A1
Authority
EP
European Patent Office
Prior art keywords
aliphatic group
hydrogen atom
tanning
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22306769.5A
Other languages
German (de)
French (fr)
Inventor
Loic FONTAINE
Thomas Lecourt
Alexandra Le Foll
Stéphane MARCOTTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Hermes Sellier SAS
Institut National des Sciences Appliquees de Rouen
Universite de Rouen Normandie
Original Assignee
Centre National de la Recherche Scientifique CNRS
Hermes Sellier SAS
Institut National des Sciences Appliquees de Rouen
Universite de Rouen Normandie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Hermes Sellier SAS, Institut National des Sciences Appliquees de Rouen, Universite de Rouen Normandie filed Critical Centre National de la Recherche Scientifique CNRS
Priority to EP22306769.5A priority Critical patent/EP4379067A1/en
Publication of EP4379067A1 publication Critical patent/EP4379067A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C14SKINS; HIDES; PELTS; LEATHER
    • C14CCHEMICAL TREATMENT OF HIDES, SKINS OR LEATHER, e.g. TANNING, IMPREGNATING, FINISHING; APPARATUS THEREFOR; COMPOSITIONS FOR TANNING
    • C14C3/00Tanning; Compositions for tanning
    • C14C3/02Chemical tanning
    • C14C3/08Chemical tanning by organic agents

Definitions

  • the present invention relates to the field of tanning. More particularly, the present invention relates to particular iridoid derivatives and their use in a tanning process. It also relates to a process for cross-linking collagen using such iridoid derivatives.
  • Natural tannins have long been used in processes for tanning hides and stabilizing collagen.
  • Tanning mixtures are mainly composed of polyphenolic tannins, which are divided into two classes: condensed tannins and hydrolysable tannins.
  • the effectiveness of tanning is usually reflected by its ability to stabilize collagen, namely to limit collagen denaturation and impart good resistance to enzymatic hydrolysis.
  • Collagen stabilization can be assessed by measuring the increase in shrinkage temperature, which is correlated to the collagen denaturation temperature.
  • the polyphenolic tannins give rise to a shrinkage temperature around 75-85°C.
  • Other parameters can also be considered for assessing the effectiveness of tanning, such as the mechanical resistance of the hide and its sensory parameters, such as hide filling and suppleness.
  • genipin can be obtained from the fruit of Gardenia jasminoides or Genipa americana. Genipin allows to stabilize collagen and to reach shrinkage temperatures of 80°C ( Zhang et al., JALCA, 2011, 106, 121 ). Genipin has also been used in combination with an aluminum-based tanning ( Ding et al., JALCA, 2008, 103, 377 ), which resulted in a soft and full leather having a shrinkage temperature of 92°C.
  • Genipin has also been used to cross-link gelatin ( Taylor et al., JALCA, 2009, 104, 79 ). Genipin is readily available in large quantities and is a known food coloring agent. However, using genepin in a tanning process leads to a dark blue color, which can be undesirable.
  • WO2009/065915 describes a tanning method using aglycone derivatives of iridoids and seco-iridoids, different from genipin.
  • Such derivatives which can be extracted from olive leaves, are hydrolyzed forms and aglycone forms of oleuropein.
  • the mixture obtained by extraction of the leaves in the presence of endogenous enzyme or by the use of acid is not purified and comprises polyphenolic compounds and compounds derived from hydrolyzed oleuropein, such as (4E)-4-formyl-3-(-1-formyl-2-methoxy-2-oxoethyl)hex-4-enoic acid.
  • the inventors have demonstrated that particular derivatives of the genipin could be easily prepared in few steps, and used in a tanning process.
  • the inventors have shown that such tanning agents were at least as effective as genipin, but advantageously, did not lead to a dark color of the hide.
  • the derivatives can be produced in high amounts starting from genipin, and their high purity allows to use low amounts of tanning mixture.
  • the present invention relates to the use of a compound represented by the following formula (I), in a tanning process: wherein:
  • R 1 is a hydrogen atom or -C(O)-(C 1 -C 12 aliphatic group), preferably a hydrogen atom or -C(O)-(C 1 -C 6 alkyl).
  • R 2 is a C 1 -C 12 aliphatic group, preferably a C 1 -C 6 alkyl.
  • R 4 is -C(O)-CH 2 -R 5 , where R 5 is a hydrogen atom or -O-C(O)-(C 1 -C 12 aliphatic group), preferably a hydrogen atom or -O-C(O)-(C 1 -C 6 alkyl).
  • R 6 is hydrogen
  • R 7 is -OH or -O-C(O)-(C 1 -C 12 aliphatic group), preferably -OH or -O-C(O)-(C 1 -C 6 alkyl).
  • R 8 is -OH.
  • R 9 is a hydrogen atom or -O-C(O)-(C 1 -C 6 alkyl).
  • said compound of formula (I) is one of the following compounds:
  • said compound of formula (I) is one of the following compounds:
  • a use according to the invention is a use for tanning a hide or a skin.
  • a use according to the invention is a use in a method for manufacturing a leather or a leather substitute.
  • a use according to the invention is a use for tanning a collagen-containing material.
  • the present invention also relates to a compound of formula (I) per se , as defined herein, with the proviso that the compound is not one of the following compounds:
  • Another object of the present invention is a process for cross-linking collagen in a material comprising a step of contacting said material with a compound of formula (I) as defined herein.
  • said material is a hide or skin.
  • C x -C y in which x and y are integers, as used in the present disclosure, means that the corresponding chemical group comprises from x to y carbon atoms. If, for example, the expression C 1 -C 6 is used, it means that the corresponding chemical group may comprise from 1 to 6 carbon atoms, especially 1, 2, 3, 4, 5 or 6 carbon atoms. If, for example, the expression C 2 -C 5 is used, it means that the corresponding chemical group may comprise from 2 to 5 carbon atoms, especially 2, 3, 4, or 5 carbon atoms.
  • aliphatic refers to a non-aromatic, saturated or unsaturated, cyclic or acyclic (preferably acyclic), linear or branched hydrocarbon chain.
  • C 1 -C 12 aliphatic refers to an aliphatic having 1 to 12 carbon atoms.
  • the aliphatic may be an alkyl, an alkenyl, or an alkynyl.
  • alkyl refers to a saturated, acyclic, linear or branched hydrocarbon chain.
  • C 1 -C 6 alkyl refers to an alkyl having 1 to 6 carbon atoms. Examples of alkyl (or C 1 -C 6 alkyl) include, for instance, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, or hexyl.
  • alkenyl refers to an unsaturated, acyclic, linear or branched hydrocarbon chain, having at least one carbon-carbon double bond.
  • C 2 -C 6 alkenyl refers to an alkenyl having 2 to 6 carbon atoms. Examples of alkenyl (or C 2 -C 6 alkenyl) include for instance, ethenyl, propenyl, butenyl, pentenyl, or hexenyl.
  • alkynyl refers to an unsaturated, acyclic, linear or branched hydrocarbon chain, having at least one carbon-carbon triple bond.
  • C 2 -C 6 alkynyl refers to an alkynyl having 2 to 6 carbon atoms. Examples of alkynyl (or C 2 -C 6 alkynyl) include, for instance, ethynyl, propynyl, butynyl, pentynyl, or hexynyl.
  • aryl refers to a mono- or bi-cyclic aromatic hydrocarbon having from 6 to 12 carbon atoms.
  • aryl includes phenyl, biphenyl, or naphthyl.
  • the aryl is a phenyl.
  • the present invention relates to the use of a compound represented by the following formula (I), in a tanning process: wherein:
  • stereoisomer refers to compounds which have identical molecular formulae as identified herein but which differ in the layout of their atoms in space. Stereoisomers which are not mirror images of each other, are designated as “diastereoisomers”, and stereoisomers which are non-superposable mirror images of each other are designated as "enantiomers” or “optical isomers”. “Stereoisomers” refer to racemates, enantiomers and diastereoisomers.
  • the compound of formula (I) as defined herein is a compound of formula (III), a compound of formula (IV), or a mixture thereof: wherein, in formulae (III) and (IV):
  • the compound of the invention is a compound of formula (III) or a mixture (in particular, a racemic mixture) of a compound of formula (III) and a compound of formula (IV). More preferably, the compound of the invention is a compound of formula (III).
  • the "salts" of the compounds of the invention include usual salts formed from inorganic or organic acids or bases as well as quaternary ammonium salts. More specific examples of suitable acid salts include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, perchloric, fumaric, acetic, propionic, succinic, glycolic, formic, lactic, maleic, tartaric, citric, palmoic, malonic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, fumaric, toluenesulfonic, methanesulfonic, naphthalene-2-sulfonic, benzenesulfonic hydroxynaphthoic, hydroiodic, malic, steroic, tannic etc. More specific examples of suitable basic salts include sodium, lithium, potassium, magnesium, aluminum, calcium, zinc salts.
  • R 1 is a hydrogen atom, a C 1 -C 12 aliphatic group, aryl, -C(O)-(C 1 -C 12 aliphatic group), -C(O)-(aryl), -CH 2 -O-(C 1 -C 12 aliphatic group), or -CH 2 -O-(aryl), said aliphatic groups being each independently optionally substituted by an aryl, a halide, -OH, -O-(C 1 -C 12 aliphatic group), - N(C 1 -C 12 aliphatic group)(C 1 -C 12 aliphatic group), -O-C(O)-(C 1 -C 12 aliphatic group), -C(O)-O-(C 1 -C 12 aliphatic group), -C(O)-NH-(C 1 -C 12 aliphatic group), -NH-C(O)-(C 1 -C 12 aliphatic group
  • R 1 is a hydrogen atom, a C 1 -C 12 aliphatic group, aryl, -C(O)-(C 1 -C 12 aliphatic group), -C(O)-(aryl), -CH 2 -O-(C 1 -C 12 aliphatic group), or -CH 2 -O-(aryl), said aliphatic groups being each independently optionally substituted by an aryl.
  • a preferred C 1 -C 12 aliphatic group substituted by an aryl is a methyl substituted by a phenyl, namely a benzyl.
  • R 1 is a hydrogen atom, a C 1 -C 12 aliphatic group, aryl, -C(O)-(C 1 -C 12 aliphatic group), -C(O)-(aryl), -CH 2 -O-(C 1 -C 12 aliphatic group), or -CH 2 -O-(aryl), said aliphatic groups being each unsubstituted.
  • a preferred C 1 -C 12 aliphatic group in R 1 is a C 1 -C 6 alkyl.
  • R 1 is a hydrogen atom, a C 1 -C 12 aliphatic group, -C(O)-(C 1 -C 12 aliphatic group), -CH 2 -O-(C 1 -C 12 aliphatic group), said aliphatic groups being each independently optionally substituted by an aryl.
  • R 1 is a hydrogen atom or -C(O)-(C 1 -C 12 aliphatic group).
  • R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, -C(O)-(C 1 -C 6 alkyl), -CH 2 -O-(C 1 -C 6 alkyl group), said alkyl groups being each independently optionally substituted by phenyl.
  • R 1 is a hydrogen atom or a -C(O)-(C 1 -C 6 alkyl) such as -C(O)-CH 3 .
  • R 1 is -C(O)-(C 1 -C 6 alkyl), such as -C(O)-CH 3 .
  • R 2 is a hydrogen atom or a C 1 -C 12 aliphatic group. More particularly, R 2 may be a hydrogen atom or a C 1 -C 6 alkyl group.
  • R 2 is a C 1 -C 12 aliphatic group, more preferably a C 1 -C 6 alkyl, such as a methyl.
  • the compound of formula (I) is such that:
  • the compound of formula (I) is such that:
  • R 5 is a hydrogen atom, a C 1 -C 6 alkyl group, -OH, or -O-C(O)-(C 1 -C 6 alkyl group).
  • R 5 is a hydrogen atom or -O-C(O)-(C 1 -C 12 aliphatic group), more preferably a hydrogen atom or -O-C(O)-(C 1 -C 6 alkyl), even more preferably, a hydrogen atom or -O-C(O)-CH 3 .
  • R 5 ' is a hydrogen atom, a C 1 -C 6 alkyl group, -OH, or -O-C(O)-(C 1 -C 6 alkyl group).
  • R 5 ' is hydrogen atom, -OH, or -O-C(O)-CH 3 . More preferably, R 5 ' is -OH.
  • the compound of formula (I) is such that:
  • the compound of formula (I) is such that:
  • R 3 and R 4 form together a chain of formula (II) as defined herein, wherein R 6 , R 7 , R 8 , and R 9 are each independently a hydrogen atom, -OH, or -O-C(O)-(C 1 -C 12 aliphatic group).
  • the compound of formula (I) can be represented as follows: wherein R 1 , R 2 , R 6 , R 7 , R 8 , and R 9 are as defined herein.
  • stereochemistry of the compound of formula (I-II) may be as follow: wherein R 1 , R 2 , R 6 , R 7 , R 8 , and R 9 are as defined herein.
  • the compound of the invention is a compound of formula (III-II) or a mixture (in particular, a racemic mixture) of a compound of formula (III-II) and a compound of formula (IV-II). More preferably, the compound of the invention is a compound of formula (III-II).
  • each stereogenic center that is not defined encompasses both (R) and (S) configurations.
  • R 6 , R 7 , R 8 , and R 9 are each independently a hydrogen atom, -OH, or -O-C(O)-(C 1 -C 6 alkyl group).
  • At least one (preferably at least two) among R 7 , R 8 , and R 9 are not hydrogen atoms.
  • R 6 is hydrogen
  • R 7 is hydrogen, -OH or -O-C(O)-(C 1 -C 6 alkyl), for instance hydrogen, -OH or -O-C(O)-CH 3 .
  • R 7 is -OH or -O-C(O)-(C 1 -C 12 aliphatic group).
  • R 7 is -OH or -O-C(O)-(C 1 -C 6 alkyl), more preferably -OH or -O-C(O)-CH 3 .
  • R 7 is -O-C(O)-(C 1 -C 12 aliphatic group), for instance -C(O)-CH 3 .
  • R 8 is hydrogen or -OH.
  • R 8 is -OH.
  • R 9 is a hydrogen atom, -OH, or -O-C(O)-(C 1 -C 6 alkyl), preferably a hydrogen atom, -OH or -O-C(O)-CH 3 .
  • R 9 is a hydrogen atom or -O-C(O)-(C 1 -C 12 aliphatic group).
  • R 9 is a hydrogen atom or -O-C(O)-(C 1 -C 6 alkyl), more preferably a hydrogen atom or -O-C(O)-CH 3 .
  • R 9 is -O-C(O)-(C 1 -C 12 aliphatic group), for instance -C(O)-CH 3 .
  • the compound of formula (I) (or of formula (I-II)) is such that R 3 and R 4 form together a chain of formula (II) wherein:
  • the compound of formula (I) (or of formula (I-II)) is such that:
  • the compound of formula (I) (or of formula (I-II)) is such that R 3 and R 4 form together a chain of formula (II) wherein:
  • the compound of formula (I) (or of formula (I-II)) is such that:
  • the compound of formula (I) is one of the following compounds:
  • the compound of formula (I) is one of the following compounds:
  • the compound of formula (I) used in the present invention is one of the following known compounds:
  • the compound of formula (I) used in the present invention is one of the following compounds:
  • the compound of formula (I) is not one of the following compounds (including any stereoisomer thereof):
  • Compounds of the invention can be prepared by any suitable technique known to the skilled artisan.
  • compounds of the invention can be prepared as detailed in the examples.
  • such compounds can be prepared starting from genipin, and by subjecting genipin to a succession of suitable synthetic reactions, such as oxidation, reduction, dihydroxylation, and/or acylation.
  • pre-tanning agents are particularly suitable for use in a tanning process, as tanning or pre-tanning agents.
  • the "pre-tanning” refers a particular step of a tanning process, which is a preliminary step where a first tanning agent (i.e. "pre-tanning agent”) is contacted with the collagen-containing material, e.g. the hide, before being contacted with a second tanning agent (i.e. "tanning agent").
  • pre-tanning agent a first tanning agent
  • the pre-tanning agent also enables the shaving of the leather before the second tanning agent is applied.
  • a tanning process may comprise or not a pre-tanning step.
  • the compound of formula (I) according to the invention may be used as a pre-tanning agent and/or tanning agent in a process comprising a pre-tanning step.
  • it may be chosen from the group consisting of: polyphenolic extract for various vegetable, mainly gallnut, quebracho, oak, metal salt of chromium, iron, zirconium, titanium, aluminum, mainly with chloride and sulfate as counter ion, and synthetics chemicals like formol, glutaraldehyde, oxazolidine, zeolite, formol phenol (and derivate like cresol, phenol sulfonic acids) condensate, formol bisphenol (A, B, S and F) condensate, formol melamine condensate, and a mixture thereof.
  • the compound of formula (I) according to the invention may be used as a tanning agent in a tanning process not comprising a pre-tanning step.
  • the tanning process may in particular be a process for tanning a collagen-containing material, and more particularly for tanning a hide or a skin.
  • said collagen-containing material or said hide or skin, is treated (typically, contacted) with one or more compounds of formula (I), or a composition comprising the same.
  • collagen refers to naturally occurring collagens or modified collagens.
  • collagen as used herein also refers to collagens prepared using recombinant techniques.
  • the term collagen includes collagen, collagen fragments, collagen dispersion obtained from hide grinding and various purification steps (e.g. enzymatic or acidic hydrolysis), collagen fibers obtained through precipitation of dispersed or soluble collagen (e.g. salt, brine or ammoniac precipitation), collagen-like proteins, triple helical collagen, alpha chains, monomers, gelatin, trimers and combinations thereof.
  • Recombinant expression of collagen and collagen-like proteins is known in the art (see in particular EP 1,232,182 ; US 6,428,978 ; US 8,188,230 ).
  • the collagen can be a chemically-modified collagen, a truncated collagen, unmodified or post-translationally modified, or amino acid sequence-modified collagen.
  • the collagen can be plant-based collagen.
  • a collagen solution can be fibrillated into collagen fibrils.
  • collagen fibrils refer to nanofibers composed of tropocollagen or tropocollagen-like structures.
  • a recombinant collagen can comprise a collagen fragment of the amino acid sequence of a native collagen molecule capable of forming tropocollagen (trimeric collagen).
  • a recombinant collagen can also comprise a modified collagen or truncated collagen having an amino acid sequence at least 70, 80, 90, 95, 96, 97, 98, or 99% identical or similar to a native collagen amino acid sequence.
  • the collagen fragment can be a 50 kDa portion of a native collagen.
  • the collagen-containing material refers to a material comprising or consisting of collagen.
  • the collagen-containing material may be from any origin, in particular from an animal (e.g. goat, bovine such as calf, cow or cattle, ovine such as sheep or lamb, reptile such as crocodile or lizard, or fish such as trout or salmon).
  • said collagen-containing material is a hide or a skin.
  • the hide or skin may be from any animal, (e.g. goat, bovine such as calf, cow or cattle, ovine such as sheep or lamb, reptile such as crocodile or lizard, or fish such as trout or salmon).
  • the treating or contacting step may be carried out under classical conditions known to the skilled artisan.
  • the collagen-containing material in particular, said hide or skin
  • the collagen-containing material may be contacted with said one or more compounds of formula (I) in an aqueous solution, optionally comprising further auxiliary agents such as, proteins, peptides, protein hydrosylates, polyamines, pH buffer, sodium chloride, sodium sulfate, sodium citrate, ammonium chloride, naphthalene sulfonic polymer, preservatives, or slippery agent.
  • concentration of compound(s) of formula (I) in the aqueous solution is typically comprised between 0.1 wt% and 40 wt%, preferably between 0.5% and 25%.
  • the pH of the aqueous solution may be within a range from 1 to 15, preferably from 7 to 11. Said pH may be adjusted by using a buffer, such as a carbonate or phosphate buffer.
  • the treating or contacting step may be carried out at a temperature comprised between 4 °C and 70 °C, preferably between 20 °C and 50 °C, more preferably between 30 °C and 40 °C.
  • the treating or contacting step may be carried out for a duration comprised between 1 hour and 90 hours, preferably between 15 hours and 50 hours.
  • the compound(s) of formula (I) may be used in a tanning process in combination with other tanning agents, such as mineral, vegetal, organic or enzymatic tanning agents (e.g.
  • polyphenolic extract for various vegetable, mainly gallnut, quebracho, oak, metal salt of chromium, iron, zirconium, titanium, aluminum, mainly with chloride and sulfate as counter ion, and synthetics chemicals like formol, glutaraldehyde, oxazolidine, zeolite, formol phenol (and derivate like cresol, phenol sulfonic acids) condensate, formol bisphenol (A, B, S and F) condensate, formol melamine condensate, and a mixture thereof).
  • the tanning step can be carried out in a tanning drum, a reactor or any other adapted device.
  • compounds of formula (I) used according to the invention allow to obtain a high-quality leather or leather substitute.
  • said leather or leather substitute may:
  • the shrinkage temperature may in particular be suitable to shave leather and to prepare the step of tanning (i.e. the step subsequent to the pre-tanning, if present in the tanning process).
  • the high-quality grain and leather surface may in particular be suitable for aniline finishing, and be characterized by a very low shrinking of the grain.
  • compounds of formula (I) are used in a method for manufacturing a leather or leather substitute.
  • a "leather substitute” refers typically to a material having similar properties as leather, and obtained by a tanning process applied to a substitute of an animal skin or hide. Said leather or leather substitute can be used in the fashion, accessories, household's appliances and other furniture industries, and especially for manufacturing bags, shoes, watch straps, belts or wallets.
  • Another object of the present invention is a process for cross-linking collagen in a material comprising a step of contacting said material with a compound of formula (I) as defined herein.
  • Said material may in particular be a hide or skin.
  • Another object of the present invention is a compound of formula (I) per se , as defined herein, with the proviso that said compound is not one of the following compounds (including any stereoisomer thereof):
  • Genipin 1 (5 g, 22.1 mmol) was suspended in dichloromethane (90 mL) under an argon atmosphere. Pyridine (5.5 mL, 68.0 mmol, 3 eq) followed by acetic anhydride (12.5 mL, 132.2 mmol, 6 eq) were added to the mixture while stirring at room temperature. The reaction was followed by TLC (cyclohexane/AcOEt 7/3).
  • R f 0.44 (SiO 2 , cyclohexane/AcOEt 7/3).
  • the obtained yellow oil was purified by silica gel chromatography (dichloromethane/ethyl acetate 1/1) to afford a mixture of both regioisomers 3a and 3b (85:15) as a yellow oil (1.76 g, 5.11 mmol, 79 %, 1 H NMR purity > 95%).
  • the proportion of 3a vs 3b depends on the reaction time. The longer the reaction was, the more 3b was formed.
  • R f 0.23 (SiO 2 , cyclohexane/AcOEt 1/1).
  • R f 0.31 (SiO 2 , cyclohexane/AcOEt 1/1).
  • R f 0.23 (SiO 2 , cyclohexane/AcOEt 1/1).
  • Potassium carbonate (0.31 g, 2.25 mmol, 3 eq)
  • potassium ferricyanide(III) 1.234 g, 3.75 mmol, 5 eq
  • potassium osmate(VI) dihydrate 0.011 g, 0.03 mmol, 0.04 eq
  • quinuclidine 0.006 g, 0.05 mmol, 0.07 eq
  • the suspension was cooled to 0 °C and a solution of 5 (0.189 g, 0.75 mmol) in THF (2 mL) was added.
  • the orange suspension was vigorously stirred at 0 °C for 4h and sodium sulfite (0.470 g, 4.5 mmol, 6 eq) was introduced.
  • the reaction mixture was allowed to return to room temperature and, after 30 minutes, filtered over a short pad of celite.
  • the aqueous layer was extracted with EtOAc. Combined organic layers were washed with HCl aqueous solution (1M), saturated aqueous NaHCO 3 and brine, dried over MgSO 4 and evaporated under reduced pressure.
  • the yellow oil obtained was purified by silica gel chromatography (cyclohexane/ethyl acetate 4/6) to afford the targeted diol 6 (0.085 g, 0.30 mmol, 40%, 1 H NMR purity > 95%) as a yellow oil.
  • R f 0.18 (SiO 2 , cyclohexane/ethyl acetate 1/1).
  • Collagen powder (200 mg) was immersed in ultrapure water (3 mL, 1500% w/w) in a vial for rehydration. After 24 hours, the rehydrated collagen was filtered and rinsed with ultrapure water.
  • the tanning compound (10 mg, 5% w/w) was weighed into a brown vial and dissolved in a carbonate buffer solution of pH 10 (1M, 3 mL, 1500% w/w). The rehydrated collagen powder was then added. The sealed vial was heated at 37°C for 48 h with moderate stirring. The collagen powder was finally filtered and thoroughly rinsed with ultrapure water (ca. 20 mL).
  • Shrinkage temperatures were measured by Differential Scanning Calorimetry (DSC). The temperatures shown in Table 1 are average values.
  • Table 1 Tanning compound Shrinkage Temperature Colour of the collagen powder Collagen Powder 60 °C Cream-white Genipin 83 °C Dark blue Compound 2 (comparative) 83 °C Dark blue Compound 5 (comparative) 79 °C Dark green Compounds 3a + 3b (85/15) 74 °C Yellow-Orange Compound 4 75 °C Yellow-Orange Compound 6 74 °C Yellow-Orange Compound 7 74 °C Yellow-Orange Compound 8 74 °C Yellow-Orange
  • the previous protocol is repeated with compounds 6a and 6b.
  • a parameter chosen among the tanning time (Table 2), the temperature (Table 3), the tanning agent content (Table 4) or the buffer solution (Table 5) is modified.
  • the influence of the said parameter is assessed by comparing the shrinkage temperatures.
  • Tables 2 to 5 show that the compounds of the invention are versatile tanning agents, which can be used in various conditions. Moreover, Table 4 shows that a limited amount, e.g 5%, of the tanning agent is needed to give optimum tanning. When compared to WO2009/065915 and Schrmür and Meyer (IULTCS Congress Dresden, 2019 ), which describe the use of iridoids extracts, the compounds of the invention can be used in a much lower amount, which allows a lower organic content of the effluent.
  • Example 3 Tanning of calf hide with compounds 3a and 3b
  • the tanning 3a + 3b compound (600 mg, 5% w/w) was dissolved in a citric acid - sodium hydrogenophosphate buffer solution of pH 7.4 (40 mL, 300% w/w).
  • the delimed calf hide (5 cm x 5 cm, 12 g) was then added.
  • the tanning solution was agitated and heated at 35 °C in a shaking water bath. After 48 h, the tanned hide was thoroughly rinsed with water and added in a solution of gallnut (retanning agent, 1.6 g, 13% w/w) in water at pH 7 (40 mL, 300% w/w).
  • Ts Shrinkage temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to the field of tanning. More particularly, the present invention relates to particular iridoid derivatives and their use in a tanning process. It also relates to a process for cross-linking collagen using such iridoid derivatives.

Description

    TECHNICAL FIELD
  • The present invention relates to the field of tanning. More particularly, the present invention relates to particular iridoid derivatives and their use in a tanning process. It also relates to a process for cross-linking collagen using such iridoid derivatives.
  • TECHNICAL BACKGROUND
  • Natural tannins have long been used in processes for tanning hides and stabilizing collagen. Tanning mixtures are mainly composed of polyphenolic tannins, which are divided into two classes: condensed tannins and hydrolysable tannins. The effectiveness of tanning is usually reflected by its ability to stabilize collagen, namely to limit collagen denaturation and impart good resistance to enzymatic hydrolysis. Collagen stabilization can be assessed by measuring the increase in shrinkage temperature, which is correlated to the collagen denaturation temperature. The polyphenolic tannins give rise to a shrinkage temperature around 75-85°C. Other parameters can also be considered for assessing the effectiveness of tanning, such as the mechanical resistance of the hide and its sensory parameters, such as hide filling and suppleness.
  • However, due to their astringency, natural polyphenolic tannins lead to a tension of the hide. In order to limit such tension, a pre-tanning step using a metal salt, such as aluminum, iron, zirconium, titanium, or chromium, or synthetic tannins, such as glutaraldehyde or oxazolidine, is usually required.
  • Recently, a new class of natural tanning or pre-tanning agents has been identified: these are iridoids and seco-iridoids. Among these compounds, genipin can be obtained from the fruit of Gardenia jasminoides or Genipa americana. Genipin allows to stabilize collagen and to reach shrinkage temperatures of 80°C (Zhang et al., JALCA, 2011, 106, 121). Genipin has also been used in combination with an aluminum-based tanning (Ding et al., JALCA, 2008, 103, 377), which resulted in a soft and full leather having a shrinkage temperature of 92°C. Genipin has also been used to cross-link gelatin (Taylor et al., JALCA, 2009, 104, 79). Genipin is readily available in large quantities and is a known food coloring agent. However, using genepin in a tanning process leads to a dark blue color, which can be undesirable.
  • Other natural iridoids have been used in processes for tanning or pre-tanning hides. In particular, WO2009/065915 describes a tanning method using aglycone derivatives of iridoids and seco-iridoids, different from genipin. Such derivatives, which can be extracted from olive leaves, are hydrolyzed forms and aglycone forms of oleuropein. The mixture obtained by extraction of the leaves in the presence of endogenous enzyme or by the use of acid is not purified and comprises polyphenolic compounds and compounds derived from hydrolyzed oleuropein, such as (4E)-4-formyl-3-(-1-formyl-2-methoxy-2-oxoethyl)hex-4-enoic acid. Schröpfer and Meyer (IULTCS Congress Dresden, 2019) also describe using a powder of dry leaves of Ligustrum vulgare or an extract thereof, in a process for tanning hides. The extracts contain iridoids of the oleuropein and ligustaloside A and B. Leathers having shrinkage temperatures between 80 and 85°C and having a light beige to brown color are obtained. However, in such methods, the low amounts of active agents in the tanning mixture imply that a large amount of such mixture must be used to obtain sufficient tanning activity. This leads to a high organic content in tanneries effluent that need to be costly treated by waste water-treatments. In addition, the extracts have a low purity and can contain co-extracted molecules, which usually cause coloring issues.
  • Therefore, there remains a need to provide effective pre-tanning or tanning agents that overcome the aforementioned limitations.
  • SUMMARY OF THE INVENTION
  • In this respect, the inventors have demonstrated that particular derivatives of the genipin could be easily prepared in few steps, and used in a tanning process. The inventors have shown that such tanning agents were at least as effective as genipin, but advantageously, did not lead to a dark color of the hide. The derivatives can be produced in high amounts starting from genipin, and their high purity allows to use low amounts of tanning mixture.
  • Thus, the present invention relates to the use of a compound represented by the following formula (I), in a tanning process:
    Figure imgb0001
    wherein:
    • R1 is a hydrogen atom, a C1-C12 aliphatic group, aryl, -C(O)-(C1-C12 aliphatic group), -C(O)-(aryl), -CH2-O-(C1-C12 aliphatic group), or -CH2-O-(aryl), said aliphatic groups being each independently optionally substituted by an aryl, a halide, -OH, -O-(C1-C12 aliphatic group), - N(C1-C12 aliphatic group)(C1-C12 aliphatic group), -O-C(O)-(C1-C12 aliphatic group), -C(O)-O-(C1-C12 aliphatic group), -C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-(C1-C12 aliphatic group), -NH-C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-O-(C1-C12 aliphatic group), -O-C(O)-NH-(C1-C12 aliphatic group), or -O-C(O)-O-(C1-C12 aliphatic group),
    • R2 is a hydrogen atom or a (C1-C12) aliphatic group,
    • R3 is -CH2-C(O)H or -CH2-CH2-OH,
    • R4 is -C(O)-CH2-R5 or -CH(OH)-CH2-R5', where R5 and R5' are each independently a hydrogen atom, a C1-C12 aliphatic group, -OH, or -O-C(O)-(C1-C12 aliphatic group),
    or R3 and R4 form together the following chain of formula (II):
    Figure imgb0002
    wherein R6, R7, R8, and R9 are each independently a hydrogen atom, -OH, or -O-C(O)-(C1-C12 aliphatic group),
    or a salt thereof.
  • In some embodiments, R1 is a hydrogen atom or -C(O)-(C1-C12 aliphatic group), preferably a hydrogen atom or -C(O)-(C1-C6 alkyl).
  • In some embodiments, R2 is a C1-C12 aliphatic group, preferably a C1-C6 alkyl.
  • In some embodiments, R4 is -C(O)-CH2-R5, where R5 is a hydrogen atom or -O-C(O)-(C1-C12 aliphatic group), preferably a hydrogen atom or -O-C(O)-(C1-C6 alkyl).
  • In some embodiments, R6 is hydrogen.
  • In some embodiments, R7 is -OH or -O-C(O)-(C1-C12 aliphatic group), preferably -OH or -O-C(O)-(C1-C6 alkyl).
  • In some embodiments, R8 is -OH.
  • In some embodiments, R9 is a hydrogen atom or -O-C(O)-(C1-C6 alkyl).
  • In a preferred embodiment, said compound of formula (I) is one of the following compounds:
    Figure imgb0003
    Figure imgb0004
  • In another preferred embodiment, said compound of formula (I) is one of the following compounds:
    Figure imgb0005
  • In a particular embodiment, a use according to the invention is a use for tanning a hide or a skin.
  • In another particular embodiment, a use according to the invention is a use in a method for manufacturing a leather or a leather substitute.
  • In a further particular embodiment, a use according to the invention is a use for tanning a collagen-containing material.
  • The present invention also relates to a compound of formula (I) per se, as defined herein, with the proviso that the compound is not one of the following compounds:
    Figure imgb0006
  • Another object of the present invention is a process for cross-linking collagen in a material comprising a step of contacting said material with a compound of formula (I) as defined herein. In a particular embodiment, said material is a hide or skin.
  • FIGURES
    • Figure 1: Images of materials obtained after tanning of a collagen powder using compounds of the invention ( compounds 3a, 3b, 4, 6, 7, and 8) and comparative compounds (compounds 2 and 5).
    • Figure 2: Image of a material obtained after tanning of a calf hide using compounds 3a and 3b.
    DETAILED DESCRIPTION OF THE INVENTION Definitions
  • The expression "Cx-Cy" in which x and y are integers, as used in the present disclosure, means that the corresponding chemical group comprises from x to y carbon atoms. If, for example, the expression C1-C6 is used, it means that the corresponding chemical group may comprise from 1 to 6 carbon atoms, especially 1, 2, 3, 4, 5 or 6 carbon atoms. If, for example, the expression C2-C5 is used, it means that the corresponding chemical group may comprise from 2 to 5 carbon atoms, especially 2, 3, 4, or 5 carbon atoms.
  • The term "aliphatic" refers to a non-aromatic, saturated or unsaturated, cyclic or acyclic (preferably acyclic), linear or branched hydrocarbon chain. The expression "C1-C12 aliphatic" refers to an aliphatic having 1 to 12 carbon atoms. In particular, the aliphatic may be an alkyl, an alkenyl, or an alkynyl.
  • The term "alkyl" refers to a saturated, acyclic, linear or branched hydrocarbon chain. The expression "C1-C6 alkyl" refers to an alkyl having 1 to 6 carbon atoms. Examples of alkyl (or C1-C6 alkyl) include, for instance, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, or hexyl.
  • The term "alkenyl" refers to an unsaturated, acyclic, linear or branched hydrocarbon chain, having at least one carbon-carbon double bond. The expression "C2-C6 alkenyl" refers to an alkenyl having 2 to 6 carbon atoms. Examples of alkenyl (or C2-C6 alkenyl) include for instance, ethenyl, propenyl, butenyl, pentenyl, or hexenyl.
  • The term "alkynyl" refers to an unsaturated, acyclic, linear or branched hydrocarbon chain, having at least one carbon-carbon triple bond. The expression "C2-C6 alkynyl" refers to an alkynyl having 2 to 6 carbon atoms. Examples of alkynyl (or C2-C6 alkynyl) include, for instance, ethynyl, propynyl, butynyl, pentynyl, or hexynyl.
  • The term "aryl" refers to a mono- or bi-cyclic aromatic hydrocarbon having from 6 to 12 carbon atoms. For instance, the term "aryl" includes phenyl, biphenyl, or naphthyl. In a preferred embodiment, the aryl is a phenyl.
  • The present invention relates to the use of a compound represented by the following formula (I), in a tanning process:
    Figure imgb0007
    wherein:
    • R1 is a hydrogen atom, a C1-C12 aliphatic group, aryl, -C(O)-(C1-C12 aliphatic group), -C(O)-(aryl), -CH2-O-(C1-C12 aliphatic group), or -CH2-O-(aryl), said aliphatic groups being each independently optionally substituted by an aryl, a halide, -OH, -O-(C1-C12 aliphatic group), - N(C1-C12 aliphatic group)(C1-C12 aliphatic group), -O-C(O)-(C1-C12 aliphatic group), -C(O)-O-(C1-C12 aliphatic group), -C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-(C1-C12 aliphatic group), -NH-C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-O-(C1-C12 aliphatic group), -O-C(O)-NH-(C1-C12 aliphatic group), or -O-C(O)-O-(C1-C12 aliphatic group),
    • R2 is a hydrogen atom or a (C1-C12) aliphatic group,
    • R3 is -CH2-C(O)H or -CH2-CH2-OH,
    • R4 is -C(O)-CH2-R5 or -CH(OH)-CH2-R5', where R5 and R5' are each independently a hydrogen atom, a C1-C12 aliphatic group, -OH, or -O-C(O)-(C1-C12 aliphatic group),
    or R3 and R4 form together the following chain of formula (II):
    Figure imgb0008
    wherein R6, R7, R8, and R9 are each independently a hydrogen atom, -OH, or -O-C(O)-(C1-C12 aliphatic group),
    or a salt thereof.
  • Compounds of formula (I) as represented herein include all possible stereoisomers, and include not only racemic compounds but also the optically active isomers as well. The term "stereoisomer" refers to compounds which have identical molecular formulae as identified herein but which differ in the layout of their atoms in space. Stereoisomers which are not mirror images of each other, are designated as "diastereoisomers", and stereoisomers which are non-superposable mirror images of each other are designated as "enantiomers" or "optical isomers". "Stereoisomers" refer to racemates, enantiomers and diastereoisomers.
  • In a particular embodiment, the compound of formula (I) as defined herein is a compound of formula (III), a compound of formula (IV), or a mixture thereof:
    Figure imgb0009
    wherein, in formulae (III) and (IV):
    • R1, R2, R3 and R4 are as defined in formula (I),
    • when R4 is -C(O)-CH2-R5, then R5 is as defined in formula (I),
    • when R3 and R4 form together said chain of formula (II), then R6, R7, R8, and R9 are as defined in formula (I).
  • Preferably, the compound of the invention is a compound of formula (III) or a mixture (in particular, a racemic mixture) of a compound of formula (III) and a compound of formula (IV). More preferably, the compound of the invention is a compound of formula (III).
  • The "salts" of the compounds of the invention include usual salts formed from inorganic or organic acids or bases as well as quaternary ammonium salts. More specific examples of suitable acid salts include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, perchloric, fumaric, acetic, propionic, succinic, glycolic, formic, lactic, maleic, tartaric, citric, palmoic, malonic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, fumaric, toluenesulfonic, methanesulfonic, naphthalene-2-sulfonic, benzenesulfonic hydroxynaphthoic, hydroiodic, malic, steroic, tannic etc. More specific examples of suitable basic salts include sodium, lithium, potassium, magnesium, aluminum, calcium, zinc salts.
  • R1 is a hydrogen atom, a C1-C12 aliphatic group, aryl, -C(O)-(C1-C12 aliphatic group), -C(O)-(aryl), -CH2-O-(C1-C12 aliphatic group), or -CH2-O-(aryl), said aliphatic groups being each independently optionally substituted by an aryl, a halide, -OH, -O-(C1-C12 aliphatic group), - N(C1-C12 aliphatic group)(C1-C12 aliphatic group), -O-C(O)-(C1-C12 aliphatic group), -C(O)-O-(C1-C12 aliphatic group), -C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-(C1-C12 aliphatic group), -NH-C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-O-(C1-C12 aliphatic group), -O-C(O)-NH-(C1-C12 aliphatic group), or -O-C(O)-O-(C1-C12 aliphatic group). In other words, R1 is:
    • a hydrogen atom,
    • a C1-C12 aliphatic group unsubstituted or substituted by an aryl, a halide, -OH, -O-(unsubstituted C1-C12 aliphatic group), -N(unsubstituted C1-C12 aliphatic group)(unsubstituted C1-C12 aliphatic group), -O-C(O)-(unsubstituted C1-C12 aliphatic group), -C(O)-O-(unsubstituted C1-C12 aliphatic group), -C(O)-NH-(unsubstituted C1-C12 aliphatic group), -NH-C(O)-(unsubstituted C1-C12 aliphatic group), -NH-C(O)-NH-(unsubstituted C1-C12 aliphatic group), -NH-C(O)-O-(unsubstituted C1-C12 aliphatic group), -O-C(O)-NH-(unsubstituted C1-C12 aliphatic group), or -O-C(O)-O-(unsubstituted C1-C12 aliphatic group),
    • an aryl,
    • -C(O)-(C1-C12 aliphatic group unsubstituted or substituted by an aryl, a halide, -OH, -O-(unsubstituted C1-C12 aliphatic group), -N(unsubstituted C1-C12 aliphatic group)(unsubstituted C1-C12 aliphatic group), -O-C(O)-(unsubstituted C1-C12 aliphatic group), -C(O)-O-(unsubstituted C1-C12 aliphatic group), -C(O)-NH-(unsubstituted C1-C12 aliphatic group), -NH-C(O)-(unsubstituted C1-C12 aliphatic group), -NH-C(O)-NH-(unsubstituted C1-C12 aliphatic group), -NH-C(O)-O-(unsubstituted C1-C12 aliphatic group), -O-C(O)-NH-(unsubstituted C1-C12 aliphatic group), or -O-C(O)-O-(unsubstituted C1-C12 aliphatic group)),
    • -C(O)-(aryl),
    • -CH2-O-(C1-C12 aliphatic group unsubstituted or substituted by an aryl, a halide, -OH, -O-(unsubstituted C1-C12 aliphatic group), -N(unsubstituted C1-C12 aliphatic group)(unsubstituted C1-C12 aliphatic group), -O-C(O)-(unsubstituted C1-C12 aliphatic group), -C(O)-O-(unsubstituted C1-C12 aliphatic group), -C(O)-NH-(unsubstituted C1-C12 aliphatic group), -NH-C(O)-(unsubstituted C1-C12 aliphatic group), -NH-C(O)-NH-(unsubstituted C1-C12 aliphatic group), -NH-C(O)-O-(unsubstituted C1-C12 aliphatic group), -O-C(O)-NH-(unsubstituted C1-C12 aliphatic group), or -O-C(O)-O-(unsubstituted C1-C12 aliphatic group)), or
    • CH2-O-(aryl).
  • Preferably, R1 is a hydrogen atom, a C1-C12 aliphatic group, aryl, -C(O)-(C1-C12 aliphatic group), -C(O)-(aryl), -CH2-O-(C1-C12 aliphatic group), or -CH2-O-(aryl), said aliphatic groups being each independently optionally substituted by an aryl.
  • A preferred C1-C12 aliphatic group substituted by an aryl is a methyl substituted by a phenyl, namely a benzyl.
  • More preferably, R1 is a hydrogen atom, a C1-C12 aliphatic group, aryl, -C(O)-(C1-C12 aliphatic group), -C(O)-(aryl), -CH2-O-(C1-C12 aliphatic group), or -CH2-O-(aryl), said aliphatic groups being each unsubstituted.
  • A preferred C1-C12 aliphatic group in R1 is a C1-C6 alkyl.
  • In another particular embodiment, R1 is a hydrogen atom, a C1-C12 aliphatic group, -C(O)-(C1-C12 aliphatic group), -CH2-O-(C1-C12 aliphatic group), said aliphatic groups being each independently optionally substituted by an aryl. In a more particular embodiment, R1 is a hydrogen atom or -C(O)-(C1-C12 aliphatic group).
  • In a more particular embodiment, R1 is a hydrogen atom, a C1-C6 alkyl group, -C(O)-(C1-C6 alkyl), -CH2-O-(C1-C6 alkyl group), said alkyl groups being each independently optionally substituted by phenyl.
  • Preferably, R1 is a hydrogen atom or a -C(O)-(C1-C6 alkyl) such as -C(O)-CH3.
  • More preferably, R1 is -C(O)-(C1-C6 alkyl), such as -C(O)-CH3.
  • R2 is a hydrogen atom or a C1-C12 aliphatic group. More particularly, R2 may be a hydrogen atom or a C1-C6 alkyl group.
  • Preferably, R2 is a C1-C12 aliphatic group, more preferably a C1-C6 alkyl, such as a methyl.
  • In a preferred embodiment, the compound of formula (I) is such that:
    • R1 is a hydrogen atom or -C(O)-(C1-C6 alkyl); and
    • R2 is a C1-C6 alkyl group.
  • In a particular embodiment, the compound of formula (I) is such that:
    • R3 is -CH2-C(O)H or -CH2-CH2-OH (preferably -CH2-C(O)H); and
    • R4 is -C(O)-CH2-R5 or -CH(OH)-CH2-R5', where R5 and R5' are each independently a hydrogen atom, a C1-C12 aliphatic group, -OH, or -O-C(O)-(C1-C12 aliphatic group). Preferably, R4 is -C(O)-CH2-R5, where R5 is as defined herein.
  • In particular, R5 is a hydrogen atom, a C1-C6 alkyl group, -OH, or -O-C(O)-(C1-C6 alkyl group).
  • Preferably, R5 is a hydrogen atom or -O-C(O)-(C1-C12 aliphatic group), more preferably a hydrogen atom or -O-C(O)-(C1-C6 alkyl), even more preferably, a hydrogen atom or -O-C(O)-CH3.
  • In particular, R5' is a hydrogen atom, a C1-C6 alkyl group, -OH, or -O-C(O)-(C1-C6 alkyl group). Preferably, R5' is hydrogen atom, -OH, or -O-C(O)-CH3. More preferably, R5' is -OH.
  • In a preferred embodiment, the compound of formula (I) is such that:
    • R3 is -CH2-C(O)H; and
    • R4 is -C(O)-CH2-R5, where R5 is a hydrogen atom or -O-C(O)-(C1-C6 alkyl) (such as -O-C(O)-CH3).
  • In a more preferred embodiment, the compound of formula (I) is such that:
    • R1 is a -C(O)-(C1-C6 alkyl);
    • R2 is a C1-C6 alkyl group;
    • R3 is -CH2-C(O)H; and
    • R4 is -C(O)-CH2-R5, where R5 is a hydrogen atom or -O-C(O)-(C1-C6 alkyl) (such as -O-C(O)-CH3).
  • In another particular embodiment, R3 and R4 form together a chain of formula (II) as defined herein, wherein R6, R7, R8, and R9 are each independently a hydrogen atom, -OH, or -O-C(O)-(C1-C12 aliphatic group). In such embodiment, the compound of formula (I) can be represented as follows:
    Figure imgb0010
    wherein R1, R2, R6, R7, R8, and R9 are as defined herein.
  • More particularly, the stereochemistry of the compound of formula (I-II) may be as follow:
    Figure imgb0011
    wherein R1, R2, R6, R7, R8, and R9 are as defined herein.
  • Preferably, the compound of the invention is a compound of formula (III-II) or a mixture (in particular, a racemic mixture) of a compound of formula (III-II) and a compound of formula (IV-II). More preferably, the compound of the invention is a compound of formula (III-II).
  • It is understood that, in any formula represented herein, such as formula (I), (II), (III), (IV), (I-II), (III-II) or (IV-II), each stereogenic center that is not defined encompasses both (R) and (S) configurations.
  • In a particular embodiment, R6, R7, R8, and R9 are each independently a hydrogen atom, -OH, or -O-C(O)-(C1-C6 alkyl group).
  • In a particular embodiment, at least one (preferably at least two) among R7, R8, and R9 (for instance, all of R7, R8, and R9) are not hydrogen atoms.
  • In a preferred embodiment, R6 is hydrogen.
  • In a particular embodiment, R7 is hydrogen, -OH or -O-C(O)-(C1-C6 alkyl), for instance hydrogen, -OH or -O-C(O)-CH3.
  • In another particular embodiment, R7 is -OH or -O-C(O)-(C1-C12 aliphatic group).
  • Preferably, R7 is -OH or -O-C(O)-(C1-C6 alkyl), more preferably -OH or -O-C(O)-CH3.
  • In another particular embodiment, R7 is -O-C(O)-(C1-C12 aliphatic group), for instance -C(O)-CH3.
  • In a particular embodiment, R8 is hydrogen or -OH. Preferably, R8 is -OH.
  • In a particular embodiment, R9 is a hydrogen atom, -OH, or -O-C(O)-(C1-C6 alkyl), preferably a hydrogen atom, -OH or -O-C(O)-CH3.
  • In a more particular embodiment, R9 is a hydrogen atom or -O-C(O)-(C1-C12 aliphatic group). Preferably, R9 is a hydrogen atom or -O-C(O)-(C1-C6 alkyl), more preferably a hydrogen atom or -O-C(O)-CH3.
  • In another particular embodiment, R9 is -O-C(O)-(C1-C12 aliphatic group), for instance -C(O)-CH3.
  • In a particular embodiment, the compound of formula (I) (or of formula (I-II)) is such that R3 and R4 form together a chain of formula (II) wherein:
    • R6 is hydrogen;
    • R7 is hydrogen, -OH or -O-C(O)-(C1-C6 alkyl), preferably hydrogen, -OH or -O-C(O)-CH3;
    • R8 is hydrogen or -OH; and
    • R9 is a hydrogen atom, -OH, or -O-C(O)-(C1-C6 alkyl), preferably a hydrogen atom, -OH, or
    • O-C(O)-CH3.
  • In a more particular embodiment, the compound of formula (I) (or of formula (I-II)) is such that:
    • R1 is a hydrogen atom or -C(O)-(C1-C6 alkyl);
    • R2 is a C1-C6 alkyl group;
    • R3 and R4 form together a chain of formula (II) wherein:
      • R6 is hydrogen;
      • R7 is hydrogen, -OH or -O-C(O)-(C1-C6 alkyl), preferably hydrogen, -OH or - O-C(O)-CH3;
      • R8 is hydrogen or -OH; and
      • R9 is a hydrogen atom, -OH, or -O-C(O)-(C1-C6 alkyl), preferably a hydrogen atom, -OH, or -O-C(O)-CH3.
  • In a preferred embodiment, the compound of formula (I) (or of formula (I-II)) is such that R3 and R4 form together a chain of formula (II) wherein:
    • R6 is hydrogen;
    • R7 is OH or -O-C(O)-(C1-C6 alkyl), preferably -OH or -O-C(O)-CH3;
    • R8 is -OH; and
    • R9 is a hydrogen atom or -O-C(O)-(C1-C6 alkyl), preferably a hydrogen atom or -O-C(O)-CH3.
  • In a more preferred embodiment, the compound of formula (I) (or of formula (I-II)) is such that:
    • R1 is a hydrogen atom or -C(O)-(C1-C6 alkyl);
    • R2 is a C1-C6 alkyl group;
    • R3 and R4 form together a chain of formula (II) wherein:
      • R6 is hydrogen;
      • R7 is OH or -O-C(O)-(C1-C6 alkyl), preferably -OH or -O-C(O)-CH3;
      • R8 is -OH; and
      • R9 is a hydrogen atom or -O-C(O)-(C1-C6 alkyl), preferably a hydrogen atom or -O-C(O)-CH3.
  • In a preferred embodiment, the compound of formula (I) is one of the following compounds:
    Figure imgb0012
    Figure imgb0013
  • More preferably, the compound of formula (I) is one of the following compounds:
    Figure imgb0014
    Figure imgb0015
  • In another preferred embodiment, the compound of formula (I) used in the present invention is one of the following known compounds:
    Figure imgb0016
  • More preferably, the compound of formula (I) used in the present invention is one of the following compounds:
    Figure imgb0017
  • In a particular embodiment, the compound of formula (I) is not one of the following compounds (including any stereoisomer thereof):
    Figure imgb0018
  • Compounds of the invention can be prepared by any suitable technique known to the skilled artisan. In particular, compounds of the invention can be prepared as detailed in the examples. For instance, such compounds can be prepared starting from genipin, and by subjecting genipin to a succession of suitable synthetic reactions, such as oxidation, reduction, dihydroxylation, and/or acylation.
  • Compounds of formula (I) as defined herein are particularly suitable for use in a tanning process, as tanning or pre-tanning agents. The "pre-tanning" refers a particular step of a tanning process, which is a preliminary step where a first tanning agent (i.e. "pre-tanning agent") is contacted with the collagen-containing material, e.g. the hide, before being contacted with a second tanning agent (i.e. "tanning agent"). Advantageously, the pre-tanning also enables the shaving of the leather before the second tanning agent is applied.
  • A tanning process may comprise or not a pre-tanning step. The compound of formula (I) according to the invention may be used as a pre-tanning agent and/or tanning agent in a process comprising a pre-tanning step. In such embodiment, if one among the pre-tanning agent and the tanning agent is not a compound of formula (I), it may be chosen from the group consisting of: polyphenolic extract for various vegetable, mainly gallnut, quebracho, oak, metal salt of chromium, iron, zirconium, titanium, aluminum, mainly with chloride and sulfate as counter ion, and synthetics chemicals like formol, glutaraldehyde, oxazolidine, zeolite, formol phenol (and derivate like cresol, phenol sulfonic acids) condensate, formol bisphenol (A, B, S and F) condensate, formol melamine condensate, and a mixture thereof.
  • The compound of formula (I) according to the invention may be used as a tanning agent in a tanning process not comprising a pre-tanning step.
  • The tanning process may in particular be a process for tanning a collagen-containing material, and more particularly for tanning a hide or a skin.
  • In said tanning process, said collagen-containing material, or said hide or skin, is treated (typically, contacted) with one or more compounds of formula (I), or a composition comprising the same.
  • As used herein, the term "collagen" refers to naturally occurring collagens or modified collagens. The term "collagen" as used herein also refers to collagens prepared using recombinant techniques. The term collagen includes collagen, collagen fragments, collagen dispersion obtained from hide grinding and various purification steps (e.g. enzymatic or acidic hydrolysis), collagen fibers obtained through precipitation of dispersed or soluble collagen (e.g. salt, brine or ammoniac precipitation), collagen-like proteins, triple helical collagen, alpha chains, monomers, gelatin, trimers and combinations thereof. Recombinant expression of collagen and collagen-like proteins is known in the art (see in particular EP 1,232,182 ; US 6,428,978 ; US 8,188,230 ). In some embodiments, the collagen can be a chemically-modified collagen, a truncated collagen, unmodified or post-translationally modified, or amino acid sequence-modified collagen. In some embodiments, the collagen can be plant-based collagen. In some embodiments, a collagen solution can be fibrillated into collagen fibrils. As used herein, collagen fibrils refer to nanofibers composed of tropocollagen or tropocollagen-like structures. In some embodiments, a recombinant collagen can comprise a collagen fragment of the amino acid sequence of a native collagen molecule capable of forming tropocollagen (trimeric collagen). A recombinant collagen can also comprise a modified collagen or truncated collagen having an amino acid sequence at least 70, 80, 90, 95, 96, 97, 98, or 99% identical or similar to a native collagen amino acid sequence. In some embodiments, the collagen fragment can be a 50 kDa portion of a native collagen. Methods of producing recombinant collagen and recombinant collagen fragments are known in the art. (see in particular US 2019/0002893 , US 2019/0040400 , US 2019/0093116 , and US 2019/0092838 ).
  • The collagen-containing material refers to a material comprising or consisting of collagen. The collagen-containing material may be from any origin, in particular from an animal (e.g. goat, bovine such as calf, cow or cattle, ovine such as sheep or lamb, reptile such as crocodile or lizard, or fish such as trout or salmon). In a particular embodiment, said collagen-containing material is a hide or a skin. The hide or skin may be from any animal, (e.g. goat, bovine such as calf, cow or cattle, ovine such as sheep or lamb, reptile such as crocodile or lizard, or fish such as trout or salmon).
  • The treating or contacting step may be carried out under classical conditions known to the skilled artisan. For instance, the collagen-containing material (in particular, said hide or skin) may be contacted with said one or more compounds of formula (I) in an aqueous solution, optionally comprising further auxiliary agents such as, proteins, peptides, protein hydrosylates, polyamines, pH buffer, sodium chloride, sodium sulfate, sodium citrate, ammonium chloride, naphthalene sulfonic polymer, preservatives, or slippery agent. The concentration of compound(s) of formula (I) in the aqueous solution is typically comprised between 0.1 wt% and 40 wt%, preferably between 0.5% and 25%. The pH of the aqueous solution may be within a range from 1 to 15, preferably from 7 to 11. Said pH may be adjusted by using a buffer, such as a carbonate or phosphate buffer. The treating or contacting step may be carried out at a temperature comprised between 4 °C and 70 °C, preferably between 20 °C and 50 °C, more preferably between 30 °C and 40 °C. The treating or contacting step may be carried out for a duration comprised between 1 hour and 90 hours, preferably between 15 hours and 50 hours. In some embodiments, the compound(s) of formula (I) may be used in a tanning process in combination with other tanning agents, such as mineral, vegetal, organic or enzymatic tanning agents (e.g. polyphenolic extract for various vegetable, mainly gallnut, quebracho, oak, metal salt of chromium, iron, zirconium, titanium, aluminum, mainly with chloride and sulfate as counter ion, and synthetics chemicals like formol, glutaraldehyde, oxazolidine, zeolite, formol phenol (and derivate like cresol, phenol sulfonic acids) condensate, formol bisphenol (A, B, S and F) condensate, formol melamine condensate, and a mixture thereof). The tanning step can be carried out in a tanning drum, a reactor or any other adapted device.
  • Advantageously, compounds of formula (I) used according to the invention allow to obtain a high-quality leather or leather substitute. In particular, said leather or leather substitute may:
    • be colorless or slightly colored (for instance, yellow, orange, beige), and/or
    • have a shrinkage temperature of at least 65°C (for instance from 65°C to 90°C), or at least 70 °C (for instance, from 70°C to 85°C), as measured by DSC, and/or
    • have a high-quality grain and leather surface.
  • The shrinkage temperature may in particular be suitable to shave leather and to prepare the step of tanning (i.e. the step subsequent to the pre-tanning, if present in the tanning process). The high-quality grain and leather surface may in particular be suitable for aniline finishing, and be characterized by a very low shrinking of the grain.
  • Hence, in a particular embodiment, compounds of formula (I) are used in a method for manufacturing a leather or leather substitute. A "leather substitute" refers typically to a material having similar properties as leather, and obtained by a tanning process applied to a substitute of an animal skin or hide. Said leather or leather substitute can be used in the fashion, accessories, household's appliances and other furniture industries, and especially for manufacturing bags, shoes, watch straps, belts or wallets.
  • Another object of the present invention is a process for cross-linking collagen in a material comprising a step of contacting said material with a compound of formula (I) as defined herein. Said material may in particular be a hide or skin.
  • Another object of the present invention is a compound of formula (I) per se, as defined herein, with the proviso that said compound is not one of the following compounds (including any stereoisomer thereof):
    Figure imgb0019
  • The invention will also be described in further detail in the following examples, which are not intended to limit the scope of this invention, as defined by the attached claims.
  • EXAMPLES Example 1: Preparation of compounds of formula (I) a) Compounds 3a and 3b
  • Figure imgb0020
  • Genipin 1 (5 g, 22.1 mmol) was suspended in dichloromethane (90 mL) under an argon atmosphere. Pyridine (5.5 mL, 68.0 mmol, 3 eq) followed by acetic anhydride (12.5 mL, 132.2 mmol, 6 eq) were added to the mixture while stirring at room temperature. The reaction was followed by TLC (cyclohexane/AcOEt 7/3).
  • After 2.5 h, MeOH (5 mL, 5.6 eq) was added and the mixture was stirred for 20 minutes. The crude was concentrated under reduced pressure and then filtered on a pad of celite/K2CO3. After evaporation of solvents under reduced pressure, the remaining oil was purified by silica gel chromatography (cyclohexane/AcOEt 7:3) to give genipin diacetate 2 (6.74 g, 21.73 mmol, 98%) as a yellow oil.
  • 1H NMR (300 MHz, CDCl3) δ (ppm) 7.45 (s, 1H, H-3), 5.93 (br s , 1H, H-7), 5.88 (d, J = 7.3 Hz, 1H, H-1), 4.71 (d, J = 13.5 Hz, 1H, H-10a), 4.59 (d, J = 13.5 Hz, 1H, H-10b), 3.74 (s, 3H, OMe), 3.28 (q, J = 7.8 Hz, 1H, H-5), 2.95-2.82 (m, 1H, H-6a), 2.89-2.82 (m, 1H, H-9), 2.24-2.21 (m, 1H, H-6b), 2.16 (s, 3H, CH 3 -C=O), 2.08 (3H, s, CH 3 -C=O).
  • 13C NMR (75 MHz, CDCl3) δ (ppm) 170.6 (C=O), 169.4 (C=O), 167.3 (C=O), 151.7 (C-3), 136.6 (C-4), 132.9 (C-7), 111.3 (C-8), 91.8 (C-1), 61.7 (C-10), 51.4 (O=C-O-CH3), 45.2 (C-9), 38.7 (C-6), 34.7 (C-5), 21.0 (CH3-C=O), 20.9 (CH3-C=O).
  • FT-IR (neat) v (cm-1) 2951; 2854; 1739; 1705; 1634; 1437; 1378; 1365; 1282; 1221; 1178; 1078.
  • HRMS (ESI) m/z: calculated for C15H22NO7 [M + NH4]+ 328.1396 ; found 328,1392.
  • Rf = 0.44 (SiO2, cyclohexane/AcOEt 7/3).
  • Potassium carbonate (2.67 g, 19.34 mmol, 3 eq), potassium ferricyanide (III) (10.61 g, 32.23 mmol, 5 eq), potassium osmate (VI) dihydrate (0.095 g, 0.26 mmol, 0.04 eq), and quinuclidine (0.057 g, 0.51 mmol, 0.08 eq) were suspended in THF/ H2O (4/5, 57 mL). After 5 min of stirring, methanesulfonamide (0.613 g, 6.45 mmol, 1 eq) was added. Then a solution of genipin diacetate 2 (2.00 g, 6.45 mmol) in THF (7 mL) was added to the reaction mixture. The dark suspension was vigorously stirred at room temperature for 1h and sodium sulfite (4.06 g, 32.21 mmol, 5 eq) was introduced. After 20 min, ethyl acetate (50 mL) was added and the mixture was vigorously stirred overnight. After filtration over a pad of celite, the aqueous layer was extracted with EtOAc. Combined organic layers were washed with HCl aqueous solution (1M), saturated aqueous NaHCO3 and brine, dried over MgSO4, filtered, and evaporated under reduced pressure. The obtained yellow oil was purified by silica gel chromatography (dichloromethane/ethyl acetate 1/1) to afford a mixture of both regioisomers 3a and 3b (85:15) as a yellow oil (1.76 g, 5.11 mmol, 79 %, 1H NMR purity > 95%).
  • The proportion of 3a vs 3b depends on the reaction time. The longer the reaction was, the more 3b was formed.
  • 3a :
    1H NMR (300 MHz, CDCl3) δ (ppm) 7.34 (d, J = 1.0 Hz, 1H, H-3), 6.31 (d, J = 3.5 Hz, 1H, H-1), 4,24 (d, J = 12.1 Hz, 1H, H-10a), 4.09 (d, J = 12.1 Hz, 1H, H-10b), 3.95 (br.s/t, 1H, H-7), 3.74 (s, 3H, O-CH 3 ), 3.22 (m, 1H, H-5), 2.67 (dd, J = 9.73 Hz, J = 3.51 Hz, 1H, H-9), 2.30 (m, 1H, H-6a), 2.09 (s, 3H, CH 3 -C=O), 2.08 (s, 3H, CH 3 -C=O), 1.87 (m, 1H, H-6b).
  • 13C NMR (75 MHz, CDCl3) δ (ppm) 171.6 ppm (C=O), 169.4 ppm (C=O), 166.9 (C=O), 150.5 (C-3), 112.2 (C-4), 88.8 (C-1), 79.9 (C-8), 73.3 (C-7), 65.9 (C-10), 51.6 (O=C-O-CH3), 47.2 (C-9), 36.8 (C-6), 27.3 (C-5), 21.0 (O=C-CH3), 20.9 (O=C-CH3).
  • FT-IR (neat) v (cm-1) 3464; 2954; 1740; 1706; 1642; 1438; 1372; 1225; 1179; 1081; 1036; 1014; 947; 883; 767.
  • HRMS (ESI) m/z: calculated for C15H20O9Na [M + Na]+ 367.1005 ; found 367.1002.
  • Rf = 0.23 (SiO2, cyclohexane/AcOEt 1/1).
  • 3b :
    Due to epimerization on position 1, two diastereoisomers of 3b were obtained.
  • 1H NMR (300 MHz, CDCl3) δ (ppm) 7.41 (d, J = 1.1 Hz, 1H, H-3'), 7.39 (d, J = 1.3 Hz, 1H, H-3), 5.53 (t, 1H H-1), 5.27 (m, 1H, H-1'), 5.27 (m, 1H, H-7), 5.11 (q, 1H, H-7') 4,39 (d, J = 11.9 Hz, 1H, H-10a), 4.26 (m, 1H, H-10b, H-10a', H-10b'), 3.72 (s, 3H, O-CH 3 ), 3.71 (s, 3H, O-CH 3 '), 3.35 (m, 1H, H-5), 2.53 (m, 1H, H-9), 2.36 (m, 1H, H-6a'), 2.22 (dd, J = 9.8 Hz, J = 7.1 Hz, 2H, H-6a, H-6b), 2.11 (s, 3H, CH 3 -C=O), 2.10 (s, 3H, CH 3 -C=O, CH 3 -C=O', CH 3 -C=O'), 1.96 (m, 1H, H-6b').
  • 13C NMR (75 MHz, CDCl3) δ (ppm) 171.6 ppm (C=O), 169.4 ppm (C=O), 166.9 (C=O), 150.5 (C-3), 112.2 (C-4), 88.8 (C-1), 79.9 (C-8), 73.3 (C-7), 65.9 (C-10), 51.6 (O=C-O-CH3), 47.2 (C-9), 36.8 (C-6), 27.3 (C-5), 21.0 (O=C-CH3), 20.9 (O=C-CH3).
  • IR: 3398; 2954; 1706; 1636; 1439; 1373; 1232; 1156; 1081; 1045; 769; 731.
  • HRMS (ESI) m/z: calculated for C15H20O9Na [M + Na]+ 367.1005 ; found 367.1005.
  • Rf = 0.31 (SiO2, cyclohexane/AcOEt 1/1).
  • b) Compound 4
  • Figure imgb0021
  • A mixture of diols 3a and 3b (85/15, 228 mg, 0.66 mmol) was dissolved in dichloromethane (7 mL) under an argon atmosphere. Pyridine (0.16 mL, 1.99 mmol, 3 eq) followed by acetic anhydride (0.37 mL, 3.96 mmol, 6 eq) were added to the mixture while stirring at room temperature. The reaction was followed by TLC (cyclohexane/AcOEt 2/3).
  • After 19 h, MeOH (0.2 mL) was added and the mixture was stirred for 20 minutes. The crude was concentrated under reduced pressure and then filtered on a pad of celite/K2CO3. After evaporation of solvents under reduced pressure, the remaining oil was purified by silica gel chromatography (cyclohexane/AcOEt 85/15 to 70/30) desired product 4 (0.094 g, 0.24 mmol, 37 %, 1H NMR purity > 95%) as a white solid.
  • 1H NMR (300 MHz, CDCl3) δ (ppm) 7.36 (d, J = 0.9 Hz, 1H, H-3), 6.34 (d, J = 2.8 Hz, 1H, H-1), 5.08 (dd, J = 6.1 Hz, J= 3.2 Hz, 1H, H-7), 4,18 (d, J = 12.1 Hz, 1H, H-10a), 4.12 (d, J = 12.1 Hz, 1H, H-10b), 3.72 (s, 3H, O-CH 3 ), 3.26 (m, 1H, H-5), 2.69 (dd, J = 10.3 Hz, J = 2.8 Hz, 1H, H-9), 2.42 (m, 1H, H-6a), 2.10 (s, 3H, CH 3 -C=O), 2.10 (s, 3H, CH 3 -C=O), 2.08 (s, 3H, CH 3 -C=O), 1.94 (m, 1H, H-6b).
  • 13C NMR (75 MHz, CDCl3) δ (ppm) 170.9 ppm (C=O), 170.7 ppm (C=O), 169.0 ppm (C=O), 166.6 (C=O), 150.4 (C-3), 112.3 (C-4), 88.4 (C-1), 80.4 (C-7), 75.8 (C-8), 65.4 (C-10), 51.6 (O=C-O-CH3), 46.7 (C-9), 35.3 (C-6), 26.7 (C-5), 21.2 (O=C-CH3), 21.0 (O=C-CH3), 20.8 (O=C-CH3).
  • Rf = 0.23 (SiO2, cyclohexane/AcOEt 1/1).
  • c) Compound 6
  • Figure imgb0022
  • To a solution of genipin diacetate 2 (1 g, 3.22 mmol) in ethyl acetate (30 mL) under an argon atmosphere, Pd/C catalyst (10 %, 450 mg, 0.42 mmol, 0.13 eq) was added while stirring at rt. Then, the reaction was placed under H2 atmosphere and stirred at rt (room temperature) for 1h. The flask was flushed with Ar and the mixture was filtered on a short pad of celite. Solvent was evaporated under reduced pressure and the remaining oil was purified by silica gel chromatography (cyclohexane/AcOEt from 95/5 to 80/20) to afford a colourless oil (469 mg) containing 90 % of the desired product 5 (1.67 mmol, 52 %).
  • 1H-NMR (300 MHz, CDCl3) δ (ppm) 7.43 (d, J = 1.2 Hz, 1H, H-3), 5.92 (d, J = 6.52 Hz, 1H, H-1), 5.52 (m, 1H, H-8), 3.72 (s, 3H, O-CH 3 ), 3.22 (m, 1H, H-5), 2.79 (m, 1H, H-7), 2.67 (t, J = 7.0 Hz, 1H, H-9), 2.14 (m, 2H, H-6a and H-6b), 2.14 (s, 3H, CH 3 -C=O), 1.77 (m, 3H, H-10). Rf = 0.5 (SiO2, cyclohexane/AcOEt 8/2).
  • Potassium carbonate (0.31 g, 2.25 mmol, 3 eq), potassium ferricyanide(III) (1.234 g, 3.75 mmol, 5 eq), potassium osmate(VI) dihydrate (0.011 g, 0.03 mmol, 0.04 eq), and quinuclidine (0.006 g, 0.05 mmol, 0.07 eq) were suspended in a mixture H2O/THF (6 mL, 2/1). After 5 minutes of stirring, the methanesulfonamide (0.075 g, 0.75 mmol, 1 eq) was added. The suspension was cooled to 0 °C and a solution of 5 (0.189 g, 0.75 mmol) in THF (2 mL) was added. The orange suspension was vigorously stirred at 0 °C for 4h and sodium sulfite (0.470 g, 4.5 mmol, 6 eq) was introduced. The reaction mixture was allowed to return to room temperature and, after 30 minutes, filtered over a short pad of celite. The aqueous layer was extracted with EtOAc. Combined organic layers were washed with HCl aqueous solution (1M), saturated aqueous NaHCO3 and brine, dried over MgSO4 and evaporated under reduced pressure. The yellow oil obtained was purified by silica gel chromatography (cyclohexane/ethyl acetate 4/6) to afford the targeted diol 6 (0.085 g, 0.30 mmol, 40%, 1H NMR purity > 95%) as a yellow oil.
  • 1H NMR (300 MHz, CDCl3) δ (ppm) 7.33 (d, J = 1.0 Hz, 1H, H-3), 6.33 (d, J = 1.5 Hz, 1H, H-1), 3.71 (m, 1H, H-7), 3.71 (s, 3H, O-CH 3 ), 3.17 (m, 1H, H-5), 2.60 (dd, J = 10.6 Hz, J = 1.5 Hz, 1H, H-9), 2.34 (ddd, J = 14.9 Hz, 9.4 Hz, 2.5 Hz, 1H, H-6a), 2.08 (s, 3H, CH 3 -C=O), 1.72 (m, 1H, H-6b), 1.24 (s, 3H, H-10).
  • 13C NMR (CDCl3, 75Hz) δ (ppm) 169.5 ppm (C=O), 167.2 (C=O), 149.9 (C-3), 112.8 (C-4), 89.7 (C-1), 79.2 (C-8), 78.3 (C-7), 51.5 (O=C-O-CH3), 46.6 (C-9), 37.7 (C-6), 26.1 (C-5), 21.4 (C-10), 21.1 (O=C-CH3).
  • HRMS (ESI) m/z: calculated for C13H18O7Na [M + Na]+ 309.0950 ; found 367.0951.
  • Rf = 0.18 (SiO2, cyclohexane/ethyl acetate 1/1).
  • d) Compound 7
  • Figure imgb0023
  • To a vigorously stirred suspension of chromatographic grade silica gel (900 mg) in dichloromethane (15.5 mL), was added dropwise a 0.65 M aqueous solution of NaIO4 (0.9 mL, 0.59 mmol, 1.4 eq). A flaky suspension was formed. A solution of diol 3a (142 mg, 0.41 mmol) in dichloromethane (20 mL) was then added and the reaction was monitored by TLC (cyclohexane/ethyl acetate 1/1).
  • After 2h, the reaction suspension was filtered on a sintered glass packed with Na2SO4. Solvent was evaporated under reduced pressure to afford the desired pure product 7 (115 mg, 0.34 mmol, 82 %, 1H NMR purity > 95%) as a yellow oil.
  • 1H NMR (300 MHz, CDCl3) δ (ppm) 9.55 (s, 1H, H-7), 7.46 (s, 1H, H-3), 6.25 (d, J = 9.6 Hz, 1H, H-1), 4,81 (d, J = 1.6 Hz, 2H, H-10), 3.71 (m, 1H, H-5), 3.69 (s, 3H, O-CH 3 ), 3.15 (dd, J = 9.6 Hz, J = 5.4 Hz, 1H, H-9), 2.85 (dd, J = 19.1 Hz, J = 9.0 Hz, 1H, H-6a), 2.65 (dd, J = 19.1 Hz, J = 2.8 Hz, 1H, H-6b), 2.13 (s, 3H, O=C-CH 3 ), 2.08 (s, 3H, O=C-CH 3 ).
  • 13C NMR (75 MHz, CDCl3) δ (ppm) 202.1 (C-8), 199.6 (C-7), 170.1 (O=C-CH3), 168.8 (O=C-CH3), 166.2 (O=C-O-CH3), 152.7 (C-3), 108.8 (C-4), 89.3 (C-1), 68.8 (C-10), 51.8 (O=C-O-CH3), 46.3 (C-9), 45.2 (C-6), 26.8 (C-5), 20.6 (O=C-CH3), 20.5 (O=C-CH3).
  • HRMS (ESI) m/z: calculated for C15H18O9Na [M + Na]+ 365.0849 ; found 365.0849.
  • FT-IR (neat) v (cm-1) 2956; 1705; 1639; 1438; 1374; 1228; 1179; 1082; 1047; 940; 794; 768; 731.
  • e) Compound 8
  • Figure imgb0024
  • To a vigorously stirred suspension of chromatographic grade silica gel (596 mg) in dichloromethane (10.5 mL), was added dropwise a 0.65 M aqueous solution of NaIO4 (0.6 mL, 0.39 mmol, 1.4 eq). A flaky suspension was formed. A solution of diol 6 (81 mg, 0.28 mmol) in dichloromethane (13.5 mL) was then added and the reaction was monitored by TLC (cyclohexane/ethyl acetate 6/4).
  • After 30 min, the reaction suspension was filtered on a sintered glass packed with Na2SO4. Solvent was evaporated under reduced pressure to afford the desired pure product 8 (68 mg, 0.28 mmol, 85%, 1H NMR purity > 95%) as a yellow oil.
  • 1H NMR (300 MHz, CDCl3) δ (ppm) 9.58 ppm (s, 1H, H-7), 7.46 (s, 1H, H-3), 6.25 (d, J = 9.8 Hz, 1H, H-1), 3.80 (m, 1H, H-5), 3.72 (s, 3H, O-CH 3 ), 3.10 (dd, J = 9.8 Hz, J = 5.3 Hz, 1H, H-9), 2.80 (dd, J = 18.8 Hz, J = 8.8 Hz, 1H, H-6a), 2.60 (dd, J = 18.8 Hz, J = 2.8 Hz, 1H, H-6b), 2.29 (s, 3H, H-10) 2.08 (s, 3H, O=C-CH3).
  • 13C NMR (75 MHz, CDCl3) δ (ppm) 207.0 (C-8), 199.1 (C-7), 168.8 (O=C-CH3), 164.4 (C-O-CH3), 152.8 (C-3), 109.2 (C-4), 90.0 (C-1), 51.8 (C-O-CH3), 50.3 (C-9), 45.5 (C-6), 26.4 (C-5), 20.8 (O=C-CH3).
  • Rf = 0.37 (SiO2, cyclohexane/ethyl acetate 1/1).
  • FT-IR (neat) v (cm-1) 3406; 2955; 1706; 1637; 1439; 1374; 1245; 1179; 1082; 939; 768; 731.
  • Example 2: Tanning experiments using compounds of formula (I)
  • Collagen powder (200 mg) was immersed in ultrapure water (3 mL, 1500% w/w) in a vial for rehydration. After 24 hours, the rehydrated collagen was filtered and rinsed with ultrapure water.
  • The tanning compound (10 mg, 5% w/w) was weighed into a brown vial and dissolved in a carbonate buffer solution of pH 10 (1M, 3 mL, 1500% w/w). The rehydrated collagen powder was then added. The sealed vial was heated at 37°C for 48 h with moderate stirring. The collagen powder was finally filtered and thoroughly rinsed with ultrapure water (ca. 20 mL).
  • Shrinkage temperatures were measured by Differential Scanning Calorimetry (DSC). The temperatures shown in Table 1 are average values. Table 1
    Tanning compound Shrinkage Temperature Colour of the collagen powder
    Collagen Powder 60 °C Cream-white
    Genipin 83 °C Dark blue
    Compound 2 (comparative) 83 °C Dark blue
    Compound 5 (comparative) 79 °C Dark green
    Compounds
    3a + 3b (85/15) 74 °C Yellow-Orange
    Compound
    4 75 °C Yellow-Orange
    Compound
    6 74 °C Yellow-Orange
    Compound
    7 74 °C Yellow-Orange
    Compound
    8 74 °C Yellow-Orange
  • Tanning experiments on collagen powder (Table 1, Figure 1) show that the compounds of the invention allow to reach shrinkage temperatures which are close to that obtained with genipin. In addition, a light color is obtained with the compounds of the invention, while genipin and derivatives 2 and 3 impart a dark color to the hide.
  • Impact of the tanning conditions on a tanning process using compounds 6a and 6b
  • The previous protocol is repeated with compounds 6a and 6b. A parameter chosen among the tanning time (Table 2), the temperature (Table 3), the tanning agent content (Table 4) or the buffer solution (Table 5) is modified. The influence of the said parameter is assessed by comparing the shrinkage temperatures.
  • Experiments described in Tables 2 to 5 show that the compounds of the invention are versatile tanning agents, which can be used in various conditions. Moreover, Table 4 shows that a limited amount, e.g 5%, of the tanning agent is needed to give optimum tanning. When compared to WO2009/065915 and Schröpfer and Meyer (IULTCS Congress Dresden, 2019), which describe the use of iridoids extracts, the compounds of the invention can be used in a much lower amount, which allows a lower organic content of the effluent. Table 2
    Tanning agent Tanning time Shrinkage temperature Colour of the collagen powder
    Compounds 3a + 3b 48 h 74 °C Yellow-Orange
    Compounds
    3a + 3b 24 h 74 °C Yellow-Orange
    Table 3
    Tanning agent Tanning temperature Shrinkage temperature Colour of the collagen powder
    Compounds 3a + 3b 37 °C 74 °C Yellow-Orange
    Compounds
    3a + 3b 20 °C 72 °C Light yellow
    Table 4
    Tanning agent Tanning agent content (w/w) Shrinkage temperature Colour of the collagen powder
    Compounds 3a + 3b 1 % 65 °C Pale yellow
    Compounds
    3a + 3b 3 % 72 °C Light yellow
    Compounds
    3a + 3b 5% 74 °C Yellow-Orange
    Compounds
    3a + 3b 10% 72 °C Yellow-Orange
    Compounds
    3a + 3b 20 % 71 °C Yellow-Brown
    Table 5
    Tanning agent Buffer solution Shrinkage temperature Colour of the collagen powder
    Compounds 3a + 3b pH 10(Carbonate 1 M) 74 °C Yellow-Orange
    Compounds
    3a + 3b pH 10 (Carbonate 0.5 M) 73 °C Yellow
    Compounds 3a + 3b pH 9 (Phosphate 0.5 M) 75 °C Orange-Brown
    Compounds 3a + 3b pH 8 (Phosphate 0.5 M) 74 °C Pale yellow
    Compounds
    3a + 3b pH 7 (Phosphate 0.5 M) 72 °C Pale yellow
  • Example 3: Tanning of calf hide with compounds 3a and 3b
  • The tanning 3a + 3b compound (600 mg, 5% w/w) was dissolved in a citric acid - sodium hydrogenophosphate buffer solution of pH 7.4 (40 mL, 300% w/w). The delimed calf hide (5 cm x 5 cm, 12 g) was then added. The tanning solution was agitated and heated at 35 °C in a shaking water bath. After 48 h, the tanned hide was thoroughly rinsed with water and added in a solution of gallnut (retanning agent, 1.6 g, 13% w/w) in water at pH 7 (40 mL, 300% w/w). After 2h of shaking, BM 80 (fatliquor, 400 mg, 3% w/w) was added and the solution heated at 50 °C overnight. Finally, pH was downed to 3.5 with acetic acid and the solution shaked for 24h more. The sample was dried at room temperature giving a slightly beige color leather (Figure 2).
  • Shrinkage temperature Ts was measured according to EN ISO 3380. T S = 76 ° C
    Figure imgb0025

Claims (17)

  1. Use of a compound represented by the following formula (I), in a tanning process:
    Figure imgb0026
    wherein:
    - R1 is a hydrogen atom, a C1-C12 aliphatic group, aryl, -C(O)-(C1-C12 aliphatic group), -C(O)-(aryl), -CH2-O-(C1-C12 aliphatic group), or -CH2-O-(aryl), said aliphatic groups being each independently optionally substituted by an aryl, a halide, -OH, -O-(C1-C12 aliphatic group), - N(C1-C12 aliphatic group)(C1-C12 aliphatic group), -O-C(O)-(C1-C12 aliphatic group), -C(O)-O-(C1-C12 aliphatic group), -C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-(C1-C12 aliphatic group), -NH-C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-O-(C1-C12 aliphatic group), -O-C(O)-NH-(C1-C12 aliphatic group), or -O-C(O)-O-(C1-C12 aliphatic group),
    - R2 is a hydrogen atom or a (C1-C12) aliphatic group,
    - R3 is -CH2-C(O)H or -CH2-CH2-OH,
    - R4 is -C(O)-CH2-R5 or -CH(OH)-CH2-R5', where R5 and R5' are each independently a hydrogen atom, a C1-C12 aliphatic group, -OH, or -O-C(O)-(C1-C12 aliphatic group),
    or R3 and R4 form together the following chain of formula (II):
    Figure imgb0027
    wherein R6, R7, R8, and R9 are each independently a hydrogen atom, -OH, or -O-C(O)-(C1-C12 aliphatic group),
    or a salt thereof.
  2. Use according to claim 1, wherein R1 is a hydrogen atom or -C(O)-(C1-C12 aliphatic group), preferably a hydrogen atom or -C(O)-(C1-C6 alkyl).
  3. Use according to claim 1 or 2, wherein R2 is a C1-C12 aliphatic group, preferably a C1-C6 alkyl.
  4. Use according to any one of claims 1 to 3, wherein R4 is -C(O)-CH2-R5, where R5 is a hydrogen atom or -O-C(O)-(C1-C12 aliphatic group), preferably a hydrogen atom or -O-C(O)-(C1-C6 alkyl).
  5. Use according to any one of claims 1 to 4, wherein R6 is hydrogen.
  6. Use according to any one of claims 1 to 5, wherein R7 is -OH or -O-C(O)-(C1-C12 aliphatic group), preferably -OH or -O-C(O)-(C1-C6 alkyl).
  7. Use according to any one of claims 1 to 6, wherein R8 is -OH.
  8. Use according to any one of claims 1 to 7, wherein R9 is a hydrogen atom or -O-C(O)-(C1-C6 alkyl).
  9. Use according to claim 1, wherein said compound is one of the following compounds:
    Figure imgb0028
    Figure imgb0029
  10. Use according to claim 1, wherein said compound is one of the following compounds:
    Figure imgb0030
  11. Use according to any one of claims 1 to 10, for tanning a hide or a skin.
  12. Use according to any one of claims 1 to 10, in a method for manufacturing a leather or a leather substitute.
  13. Use according to any one of claims 1 to 10, for tanning a collagen-containing material.
  14. A compound which is represented by the following formula (I):
    Figure imgb0031
    wherein:
    - R1 is a hydrogen atom, a C1-C12 aliphatic group, aryl, -C(O)-(C1-C12 aliphatic group), -C(O)-(aryl), -CH2-O-(C1-C12 aliphatic group), -CH2-O-(aryl), said aliphatic groups being each independently optionally substituted by an aryl, a halide, -OH, -O-(C1-C12 aliphatic group), - N(C1-C12 aliphatic group)(C1-C12 aliphatic group), -O-C(O)-(C1-C12 aliphatic group), -C(O)-O-(C1-C12 aliphatic group), -C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-(C1-C12 aliphatic group), -NH-C(O)-NH-(C1-C12 aliphatic group), -NH-C(O)-O-(C1-C12 aliphatic group), -O-C(O)-NH-(C1-C12 aliphatic group), or -O-C(O)-O-(C1-C12 aliphatic group),
    - R2 is a hydrogen atom or a (C1-C12) aliphatic group,
    - R3 is -CH2-C(O)H or -CH2-CH2-OH,
    - R4 is -C(O)-CH2-R5 or -CH(OH)-CH2-R5', where R5 and R5' are each independently a hydrogen atom, a C1-C12 aliphatic group, -OH, or -O-C(O)-(C1-C12 aliphatic group),
    or R3 and R4 form together the following chain of formula (II):
    Figure imgb0032
    wherein R6, R7, R8, and R9 are each independently a hydrogen atom, -OH, or -O-C(O)-(C1-C12 aliphatic group),
    or a salt thereof,
    with the proviso that said compound is not one of the following compounds:
    Figure imgb0033
  15. The compound according to claim 14, which is defined as in any one of claims 2 to 9.
  16. A process for cross-linking collagen in a material comprising a step of contacting said material with a compound as defined in any one of claims 1 to 10.
  17. The process according to claim 16, wherein said material is a hide or skin.
EP22306769.5A 2022-12-01 2022-12-01 Iridoid derivatives and their use in a tanning process Pending EP4379067A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22306769.5A EP4379067A1 (en) 2022-12-01 2022-12-01 Iridoid derivatives and their use in a tanning process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22306769.5A EP4379067A1 (en) 2022-12-01 2022-12-01 Iridoid derivatives and their use in a tanning process

Publications (1)

Publication Number Publication Date
EP4379067A1 true EP4379067A1 (en) 2024-06-05

Family

ID=84537233

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22306769.5A Pending EP4379067A1 (en) 2022-12-01 2022-12-01 Iridoid derivatives and their use in a tanning process

Country Status (1)

Country Link
EP (1) EP4379067A1 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428978B1 (en) 1998-05-08 2002-08-06 Cohesion Technologies, Inc. Methods for the production of gelatin and full-length triple helical collagen in recombinant cells
EP1232182A2 (en) 1999-11-12 2002-08-21 Fibrogen, Inc. Animal collagens and gelatins
WO2009065915A1 (en) 2007-11-23 2009-05-28 N-Zyme Biotec Gmbh Agent and method for tanning skins and pelts
US8188230B2 (en) 1997-12-24 2012-05-29 Fuji Film Manufacturing Europe B.V. Method for recombinant microorganism expression and isolation of collagen-like polypeptides
US20170080040A1 (en) * 2014-05-15 2017-03-23 Livio Pesle Decoction of olive leaves
WO2018025210A1 (en) * 2016-08-03 2018-02-08 Tannow S.R.L. Use of olive mill waste waters in the leather tanning industry
US20190002893A1 (en) 2017-06-29 2019-01-03 Modern Meadow, Inc. Yeast strains and methods for producing collagen
US20190040400A1 (en) 2017-07-31 2019-02-07 Modern Meadow, Inc. Yeast strains and methods for controlling hydroxylation of recombinant collagen
US20190093116A1 (en) 2017-09-22 2019-03-28 Modern Meadow, Inc. Recombinant yeast strains

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188230B2 (en) 1997-12-24 2012-05-29 Fuji Film Manufacturing Europe B.V. Method for recombinant microorganism expression and isolation of collagen-like polypeptides
US6428978B1 (en) 1998-05-08 2002-08-06 Cohesion Technologies, Inc. Methods for the production of gelatin and full-length triple helical collagen in recombinant cells
EP1232182A2 (en) 1999-11-12 2002-08-21 Fibrogen, Inc. Animal collagens and gelatins
WO2009065915A1 (en) 2007-11-23 2009-05-28 N-Zyme Biotec Gmbh Agent and method for tanning skins and pelts
US20170080040A1 (en) * 2014-05-15 2017-03-23 Livio Pesle Decoction of olive leaves
WO2018025210A1 (en) * 2016-08-03 2018-02-08 Tannow S.R.L. Use of olive mill waste waters in the leather tanning industry
US20190002893A1 (en) 2017-06-29 2019-01-03 Modern Meadow, Inc. Yeast strains and methods for producing collagen
US20190040400A1 (en) 2017-07-31 2019-02-07 Modern Meadow, Inc. Yeast strains and methods for controlling hydroxylation of recombinant collagen
US20190093116A1 (en) 2017-09-22 2019-03-28 Modern Meadow, Inc. Recombinant yeast strains
US20190092838A1 (en) 2017-09-22 2019-03-28 Modern Meadow, Inc. Recombinant yeast strains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DING ET AL., JALCA, vol. 103, 2008, pages 377
TAYLOR ET AL., JALCA, vol. 104, 2009, pages 79

Similar Documents

Publication Publication Date Title
US20090149666A1 (en) Method for the production of bisepoxides and dithiols
EP3237390B1 (en) Method for the industrial production of 2-halo-4,6-dialkoxy-1,3,5-triazine and their use in the presence of amines
EP4379067A1 (en) Iridoid derivatives and their use in a tanning process
KR20100111271A (en) Agent and method for tanning skins and pelts
DE2808111A1 (en) NEW DIPEPTIDE DERIVATIVES AND THEIR USE FOR MEASURING ENZYMATIC ACTIVITY
EP4379068A1 (en) Iridoid or seco-iridoid derivatives and their use in a tanning process
EP3597778B1 (en) Chrome-free tanning agents and tanning process
US6827745B1 (en) Mixture of THP and a moderator to tan leather
CN113666979B (en) Cyanuric chloride derivative and preparation method and application thereof
US2733977A (en) Process of tanning with salt of ampho-
US4936864A (en) Condensates of bis-(4-hydroxyphenyl) sulfone as tanning assistants, their preparation and use in the tanning of leather
EP0554216B1 (en) Process for pickling and pretanning of hides
JPS6014616B2 (en) Modified catalyst for sterically differentiated reduction of carbonyl compounds
DE10353746A1 (en) Method for removing horny substances from hides of dead animals
US5360454A (en) Tanning of leather and fur
SU1595913A1 (en) Method of finishing leather
RU1772158C (en) Method of hide pickling
EP0370161A2 (en) Chromium free process for the tanning of hides
SU1182082A1 (en) Method of tawing leather for shoe upper
US6251414B1 (en) Aqueous formulation for pretanning raw hides
DE2558508B2 (en) Process for the resolution of DL-pantolactone
EP0099855B1 (en) Process for the preparation of a dipeptide ester from l-aspartic acid
US644482A (en) Tanning process.
KR100209299B1 (en) Novel aminocyclic compounds
US3404151A (en) Novel hydroxyl amine triazine compounds and process for producing the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR